Cargando…
SARS-CoV-2 RNA polymerase as target for antiviral therapy
A new human coronavirus named SARS-CoV-2 was identified in several cases of acute respiratory syndrome in Wuhan, China in December 2019. On March 11 2020, WHO declared the SARS-CoV-2 infection to be a pandemic, based on the involvement of 169 nations. Specific drugs for SARS-CoV-2 are obviously not...
Autores principales: | Buonaguro, Luigi, Tagliamonte, Maria, Tornesello, Maria Lina, Buonaguro, Franco M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200052/ https://www.ncbi.nlm.nih.gov/pubmed/32370758 http://dx.doi.org/10.1186/s12967-020-02355-3 |
Ejemplares similares
-
Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example
por: Buonaguro, Luigi, et al.
Publicado: (2007) -
Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies
por: Tagliamonte, Maria, et al.
Publicado: (2011) -
Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
por: Tornesello, Anna Lucia, et al.
Publicado: (2020) -
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
por: Tornesello, Anna Lucia, et al.
Publicado: (2022) -
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
por: Buonaguro, Luigi, et al.
Publicado: (2020)